Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice

Yoko Kikumoto, Hitoshi Sugiyama, Tatsuyuki Inoue, Hiroshi Morinaga, Keiichi Takiue, Masashi Kitagawa, Naomi Fukuoka, Mizuho Saeki, Yohei Maeshima, Da Hong Wang, Keiki Ogino, Noriyoshi Masuoka, Hirofumi Makino

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Human acatalasemia may be a risk factor for the development of diabetes mellitus. However, the mechanism by which diabetes is induced is still poorly understood. The impact of catalase deficiency on the onset of diabetes has been studied in homozygous acatalasemic mutant mice or control wild-type mice by intraperitoneal injection of diabetogenic alloxan. The incidence of diabetes was higher in acatalasemic mice treated with a high dose (180 mg/kg body weight) of alloxan. A higher dose of alloxan accelerated severe atrophy of pancreatic islets and induced pancreatic β cell apoptosis in acatalasemic mice in comparison to wild-type mice. Catalase activity remained low in the acatalasemic pancreas without the significant compensatory up-regulation of glutathione peroxidase or superoxide dismutase. Furthermore, daily intraperitoneal injection of angiotensin II type 1 (AT1) receptor antagonist telmisartan (0.1 mg/kg body weight) prevented the development of alloxan-induced hyperglycemia in acatalasemic mice. This study suggests that catalase plays a crucial role in the defense against oxidative-stress-mediated pancreatic β cell death in an alloxan-induced diabetes mouse model. Treatment with telmisartan may prevent the onset of alloxan-induced diabetes even under acatalasemic conditions.

Original languageEnglish
Pages (from-to)240-246
Number of pages7
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1802
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Experimental Diabetes Mellitus
Alloxan
Apoptosis
Acatalasia
Intraperitoneal Injections
Catalase
Body Weight
Angiotensin II Type 1 Receptor Blockers
Glutathione Peroxidase
Islets of Langerhans
Hyperglycemia
Superoxide Dismutase
Atrophy
Pancreas
Diabetes Mellitus
Oxidative Stress
Cell Death
Up-Regulation
Incidence

Keywords

  • Acatalasemia
  • Angiotensin II
  • Apoptosis
  • Catalase
  • Diabetes mellitus
  • Oxidative stress
  • Receptor antagonist

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice. / Kikumoto, Yoko; Sugiyama, Hitoshi; Inoue, Tatsuyuki; Morinaga, Hiroshi; Takiue, Keiichi; Kitagawa, Masashi; Fukuoka, Naomi; Saeki, Mizuho; Maeshima, Yohei; Wang, Da Hong; Ogino, Keiki; Masuoka, Noriyoshi; Makino, Hirofumi.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1802, No. 2, 02.2010, p. 240-246.

Research output: Contribution to journalArticle

Kikumoto, Yoko ; Sugiyama, Hitoshi ; Inoue, Tatsuyuki ; Morinaga, Hiroshi ; Takiue, Keiichi ; Kitagawa, Masashi ; Fukuoka, Naomi ; Saeki, Mizuho ; Maeshima, Yohei ; Wang, Da Hong ; Ogino, Keiki ; Masuoka, Noriyoshi ; Makino, Hirofumi. / Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2010 ; Vol. 1802, No. 2. pp. 240-246.
@article{3ce7d54b01304d69becfcb3c90468f1f,
title = "Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice",
abstract = "Human acatalasemia may be a risk factor for the development of diabetes mellitus. However, the mechanism by which diabetes is induced is still poorly understood. The impact of catalase deficiency on the onset of diabetes has been studied in homozygous acatalasemic mutant mice or control wild-type mice by intraperitoneal injection of diabetogenic alloxan. The incidence of diabetes was higher in acatalasemic mice treated with a high dose (180 mg/kg body weight) of alloxan. A higher dose of alloxan accelerated severe atrophy of pancreatic islets and induced pancreatic β cell apoptosis in acatalasemic mice in comparison to wild-type mice. Catalase activity remained low in the acatalasemic pancreas without the significant compensatory up-regulation of glutathione peroxidase or superoxide dismutase. Furthermore, daily intraperitoneal injection of angiotensin II type 1 (AT1) receptor antagonist telmisartan (0.1 mg/kg body weight) prevented the development of alloxan-induced hyperglycemia in acatalasemic mice. This study suggests that catalase plays a crucial role in the defense against oxidative-stress-mediated pancreatic β cell death in an alloxan-induced diabetes mouse model. Treatment with telmisartan may prevent the onset of alloxan-induced diabetes even under acatalasemic conditions.",
keywords = "Acatalasemia, Angiotensin II, Apoptosis, Catalase, Diabetes mellitus, Oxidative stress, Receptor antagonist",
author = "Yoko Kikumoto and Hitoshi Sugiyama and Tatsuyuki Inoue and Hiroshi Morinaga and Keiichi Takiue and Masashi Kitagawa and Naomi Fukuoka and Mizuho Saeki and Yohei Maeshima and Wang, {Da Hong} and Keiki Ogino and Noriyoshi Masuoka and Hirofumi Makino",
year = "2010",
month = "2",
doi = "10.1016/j.bbadis.2009.10.009",
language = "English",
volume = "1802",
pages = "240--246",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice

AU - Kikumoto, Yoko

AU - Sugiyama, Hitoshi

AU - Inoue, Tatsuyuki

AU - Morinaga, Hiroshi

AU - Takiue, Keiichi

AU - Kitagawa, Masashi

AU - Fukuoka, Naomi

AU - Saeki, Mizuho

AU - Maeshima, Yohei

AU - Wang, Da Hong

AU - Ogino, Keiki

AU - Masuoka, Noriyoshi

AU - Makino, Hirofumi

PY - 2010/2

Y1 - 2010/2

N2 - Human acatalasemia may be a risk factor for the development of diabetes mellitus. However, the mechanism by which diabetes is induced is still poorly understood. The impact of catalase deficiency on the onset of diabetes has been studied in homozygous acatalasemic mutant mice or control wild-type mice by intraperitoneal injection of diabetogenic alloxan. The incidence of diabetes was higher in acatalasemic mice treated with a high dose (180 mg/kg body weight) of alloxan. A higher dose of alloxan accelerated severe atrophy of pancreatic islets and induced pancreatic β cell apoptosis in acatalasemic mice in comparison to wild-type mice. Catalase activity remained low in the acatalasemic pancreas without the significant compensatory up-regulation of glutathione peroxidase or superoxide dismutase. Furthermore, daily intraperitoneal injection of angiotensin II type 1 (AT1) receptor antagonist telmisartan (0.1 mg/kg body weight) prevented the development of alloxan-induced hyperglycemia in acatalasemic mice. This study suggests that catalase plays a crucial role in the defense against oxidative-stress-mediated pancreatic β cell death in an alloxan-induced diabetes mouse model. Treatment with telmisartan may prevent the onset of alloxan-induced diabetes even under acatalasemic conditions.

AB - Human acatalasemia may be a risk factor for the development of diabetes mellitus. However, the mechanism by which diabetes is induced is still poorly understood. The impact of catalase deficiency on the onset of diabetes has been studied in homozygous acatalasemic mutant mice or control wild-type mice by intraperitoneal injection of diabetogenic alloxan. The incidence of diabetes was higher in acatalasemic mice treated with a high dose (180 mg/kg body weight) of alloxan. A higher dose of alloxan accelerated severe atrophy of pancreatic islets and induced pancreatic β cell apoptosis in acatalasemic mice in comparison to wild-type mice. Catalase activity remained low in the acatalasemic pancreas without the significant compensatory up-regulation of glutathione peroxidase or superoxide dismutase. Furthermore, daily intraperitoneal injection of angiotensin II type 1 (AT1) receptor antagonist telmisartan (0.1 mg/kg body weight) prevented the development of alloxan-induced hyperglycemia in acatalasemic mice. This study suggests that catalase plays a crucial role in the defense against oxidative-stress-mediated pancreatic β cell death in an alloxan-induced diabetes mouse model. Treatment with telmisartan may prevent the onset of alloxan-induced diabetes even under acatalasemic conditions.

KW - Acatalasemia

KW - Angiotensin II

KW - Apoptosis

KW - Catalase

KW - Diabetes mellitus

KW - Oxidative stress

KW - Receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=74149091666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149091666&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2009.10.009

DO - 10.1016/j.bbadis.2009.10.009

M3 - Article

C2 - 19883754

AN - SCOPUS:74149091666

VL - 1802

SP - 240

EP - 246

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 2

ER -